Bio
We haven't found any bio for you yet.
Researcher Links
Loading links...
Publications by Type
Loading publications…
The last 5 uploaded publications
148P Safety and efficacy of atezolizumab (Atezo) + bevacizumab (Bev) in Japanese patients (pts) with unresectable hepatocellular carcinoma (uHCC): Preliminary analysis of a prospective, multicenter, observational study (ELIXIR)
Teiji Kuzuya, T. Yamashita, T. Takehara, Hiroshi Aikata, Naoya Kato, Yoichi Hiasa, Shinichiro Nakamura, N. Morimoto, M. Moriguchi, Masafumi Ikeda, Jun‐ichiro Inoue, Joji Tani, Yoshiyuki Ueno, Kazuaki Chayama, Ryosuke Tateishi, Y. Kawamura, Junji Furuse, Masatoshi Kudo, Kazuhiro Yamamoto, Norihiro Kokudo (2023). 148P Safety and efficacy of atezolizumab (Atezo) + bevacizumab (Bev) in Japanese patients (pts) with unresectable hepatocellular carcinoma (uHCC): Preliminary analysis of a prospective, multicenter, observational study (ELIXIR). , 34, DOI: https://doi.org/10.1016/j.annonc.2023.10.283.
Article24 days ago205TiP IMPACT: Randomized, multicenter, phase III study evaluating the efficacy of immunotherapy (atezolizumab) plus anti-VEGF therapy (bevacizumab) in combination with transcatheter arterial chemoembolization for unresectable hepatocellular carcinoma (HCC)
Tatsuya Yamashita, Yoshitaka Inaba, Masafumi Ikeda, Miyuki Sone, K. Yamakado, Hideyuki Nishiofuku, Kazuhiro Tsuchiya, Toshifumi Tada, Yozo Sato, Takahiro Kodama, Teiji Kuzuya, Sadahisa Ogasawara, Makoto Ueno, Hideki Iwamoto, Michihisa Moriguchi, Kazuomi Ueshima, Yoshihisa Kodama, Tetsuo Takehara, Takayuki Hamano, Masatoshi Kudo (2023). 205TiP IMPACT: Randomized, multicenter, phase III study evaluating the efficacy of immunotherapy (atezolizumab) plus anti-VEGF therapy (bevacizumab) in combination with transcatheter arterial chemoembolization for unresectable hepatocellular carcinoma (HCC). , 34, DOI: https://doi.org/10.1016/j.annonc.2023.10.784.
Article24 days agoFinal Results of TACTICS: A Randomized, Prospective Trial Comparing Transarterial Chemoembolization Plus Sorafenib to Transarterial Chemoembolization Alone in Patients with Unresectable Hepatocellular Carcinoma
Masatoshi Kudo, Kazuomi Ueshima, Masafumi Ikeda, Takuji Torimura, Nobukazu Tanabe, Hiroshi Aikata, Namiki Izumi, Takahiro Yamasaki, Shunsuke Nojiri, Keisuke Hino, Hidetaka Tsumura, Teiji Kuzuya, Norio Isoda, Michihisa Moriguchi, Hajime Aino, Akio Ido, Naoto Kawabe, Kazuhiko Nakao, Yoshiyuki Wada, Sadahisa Ogasawara, Kenichi Yoshimura, Takuji Okusaka, Junji Furuse, Norihiro Kokudo, Kiwamu Okita, Philip J. Johnson, Yasuaki Arai (2022). Final Results of TACTICS: A Randomized, Prospective Trial Comparing Transarterial Chemoembolization Plus Sorafenib to Transarterial Chemoembolization Alone in Patients with Unresectable Hepatocellular Carcinoma. , 11(4), DOI: https://doi.org/10.1159/000522547.
Article24 days agoSupplementary Material for: Final Results of TACTICS: A Randomized, Prospective Trial Comparing Transarterial Chemoembolization Plus Sorafenib to Transarterial Chemoembolization Alone in Patients with Unresectable Hepatocellular Carcinoma
Masatoshi Kudo, Kazuomi Ueshima, Masafumi Ikeda, Takuji Torimura, N. Tanabe, Hiroshi Aikata, Namiki Izumi, Takahiro Yamasaki, Shunsuke Nojiri, Keisuke Hino, Hideyasu Tsumura, Teiji Kuzuya, N. Isoda, Michihisa Moriguchi, Hiroshi Aino, Ido A, Norihiko Kawabe, Kazuwa Nakao, Yoshiyuki Wada, Sadahisa Ogasawara, Kenichi Yoshimura, Takuji Okusaka, Junji Furuse, Norihiro Kokudo, K Okita, Johnson P.J., Yasuaki Arai, on behalf of the TACTICS study groupSupplementary Material for: Final Results of TACTICS: A Randomized, Prospective Trial Comparing Transarterial Chemoembolization Plus Sorafenib to Transarterial Chemoembolization Alone in Patients with Unresectable Hepatocellular Carcinoma. , DOI: https://doi.org/10.6084/m9.figshare.19154354.
Dataset24 days agoTACTICS: Final overall survival (OS) data from a randomized, open label, multicenter, phase II trial of transcatheter arterial chemoembolization (TACE) therapy in combination with sorafenib as compared with TACE alone in patients (pts) with hepatocellular carcinoma (HCC).
Masatoshi Kudo, Kazuomi Ueshima, Masafumi Ikeda, Takuji Torimura, Hiroshi Aikata, Namiki Izumi, Takahiro Yamasaki, Keisuke Hino, Teiji Kuzuya, Norio Isoda, Kohichiroh Yasui, Hajime Aino, Akio Ido, Naoto Kawabe, Kazuhiko Nakao, Yoshiyuki Wada, Kenichi Yoshimura, Takuji Okusaka, Junji Furuse, Yasuaki Arai (2021). TACTICS: Final overall survival (OS) data from a randomized, open label, multicenter, phase II trial of transcatheter arterial chemoembolization (TACE) therapy in combination with sorafenib as compared with TACE alone in patients (pts) with hepatocellular carcinoma (HCC).. , 39(3_suppl), DOI: https://doi.org/10.1200/jco.2021.39.3_suppl.270.
Article24 days ago